TOKYO, Aug 2, 2021 - (JCN Newswire) - - Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two ...

TOKYO, Jan 18, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the ...

Perampanel was found effective and safe for prolonged use in children with epilepsy, according to one study. After its 2012 approval as an antiseizure medication, perampanel (Fycompa) has been found ...

NUTLEY, N.J., Nov. 23, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will have a total of 34 posters, including the latest data ...

Eisai has resorted to legal action in the US as it struggles to bring its recently-approved epilepsy treatment Fycompa to market. The pharma company is suing the US Drug Enforcement Administration ...

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion for Eisai's antiepileptic drug (AED) ...

This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA ...